#49249
Re: Chicharros USA - bolsa internacional
ops, perdón por ese post duplicado, no fue cosa mia, no se
#49250
Re: Chicharros USA - bolsa internacional
Por el precio por operación no me importa ya que no es muy alto más o menos 27 por operación lo que me molesta que hay muchos títulos que no los tienen
#49251
Re: Chicharros USA - bolsa internacional
ABUS presenta resultados la semana que viene? Como la veis? Lleva un mes lateral y los cortos han bajado. Alguien la tiene analizada?
#49252
Re: Chicharros USA - bolsa internacional
yo en cuento a brokers, sigo teniendo duda
tengo clicktrader, pero aqui tengo comprado acciones en real para largo plazo empresas grandes casi todas. no hay prisa y por el momento contento con la atencion y todo.
para los chicharros, por el momento estoy en virtual con IB que vi que tenia cuenta demo.
si me decido mas adelante a real con los chicharros, como veis clicktrader en cuanto a comisiones (como ya lo tengo y ademas mas que nada como tiene los valores depositados en españa a la hora de hacienda sera mas facil)
también estaba dado de alta en DEGIRO (pero esta parado por el covid) tengo numero de espera tampoco me preocupa porque al final no tengo prisa
también lei que alguno trabaja los selfbank los chicharros, que no se como funciona ese broker, no lo he llegado a mirar
también decir que ni de coña moveria 50.000
¿cual es la mejor opcion para los chicharros?
tengo clicktrader, pero aqui tengo comprado acciones en real para largo plazo empresas grandes casi todas. no hay prisa y por el momento contento con la atencion y todo.
para los chicharros, por el momento estoy en virtual con IB que vi que tenia cuenta demo.
si me decido mas adelante a real con los chicharros, como veis clicktrader en cuanto a comisiones (como ya lo tengo y ademas mas que nada como tiene los valores depositados en españa a la hora de hacienda sera mas facil)
también estaba dado de alta en DEGIRO (pero esta parado por el covid) tengo numero de espera tampoco me preocupa porque al final no tengo prisa
también lei que alguno trabaja los selfbank los chicharros, que no se como funciona ese broker, no lo he llegado a mirar
también decir que ni de coña moveria 50.000
¿cual es la mejor opcion para los chicharros?
#49253
Re: Chicharros USA - bolsa internacional
Buenos días . Parece que TRNX también se va a la mierda.
Company Accepts Outstanding Nasdaq Delisting Determination
PHOENIX, AZ, April 30, 2020 (GLOBE NEWSWIRE) -- Taronis Technologies, Inc., (“Taronis” or “the Company”) (NASDAQ: TRNX), a sustainability technologies company with patented water decontamination and conservation applications, today announced that the Company has notified Nasdaq that it will no longer contest the Nasdaq delisting notice sent to the Company on March 12, 2020. The Company had previously requested a panel hearing with Nasdaq, and was granted a hearing originally scheduled for April 16, 2020. The panel hearing was ultimately postponed on short notice, and has yet to be rescheduled. Nasdaq announced the suspension of certain ongoing listing requirements, including the minimum bid price rule the evening of April 16, 2020.
Despite the temporary regulatory relief provided by the suspension of the minimum bid price rule, the Company has decided to comply with Nasdaq’s delisting request as a result of several factors.
First, the only qualitative factor cited in the Nasdaq letter of non-compliance was the failure to satisfy the $1.00 minimum bid price. With the catastrophic impact of the coronavirus pandemic, the Company’s common stock share price has deteriorated significantly, to a point where it does not believe that the $1.00 compliance is possible through organic business activities prior to June 30, 2020.
Second, the Company has evaluated a number of possible corporate transactions with third parties that could possibly facilitate Nasdaq compliance. In every instance, the completion of such transactions would likely require a highly aggressive corporate restructuring, including a significant reverse split and the increase in authorized and outstanding shares above the current shareholder approved limits.
Lastly, none of the prospective merger candidates expressed an interest in retaining the existing assets of the Company in shareholder hands due to a desired reverse merger. The Company has evaluated the significant short term cash expenses required to complete such a speculative transaction, as well as the protracted regulatory approval process, coupled with the likely extreme dilution required to existing shareholder’s ownership and determined that the best path to preserve shareholder value is to accept the requested delisting request.
“The Company believes our current patent portfolio, expected future royalty income, and emerging commercial application for our patent portfolio should not be taken out of our shareholder’s hands in the immediate future through a possible reverse merger,” commented Scott Mahoney, CEO of Taronis. “We also wish to limit further dilution wherever possible, and all of the transactions we have evaluated would require a very sizable reverse split ratio that we believe would destroy much of our shareholder’s value.”
“We believe that once the short term disruptions to our business have passed, in the coming quarters, we will be able to resume our sterilization technology commercialization efforts. We also hope to eventually be able to regain momentum with hotels, restaurants, retirement homes, hospitals and other clients of Water Pilot.”
“In the short term, we will continue to evaluate a wide range of corporate initiatives to help unlock shareholder value on every front. These are extremely uncertain and unique times, and we are going to explore every avenue possible for our shareholders,” concluded Mr. Mahoney.
Company Accepts Outstanding Nasdaq Delisting Determination
PHOENIX, AZ, April 30, 2020 (GLOBE NEWSWIRE) -- Taronis Technologies, Inc., (“Taronis” or “the Company”) (NASDAQ: TRNX), a sustainability technologies company with patented water decontamination and conservation applications, today announced that the Company has notified Nasdaq that it will no longer contest the Nasdaq delisting notice sent to the Company on March 12, 2020. The Company had previously requested a panel hearing with Nasdaq, and was granted a hearing originally scheduled for April 16, 2020. The panel hearing was ultimately postponed on short notice, and has yet to be rescheduled. Nasdaq announced the suspension of certain ongoing listing requirements, including the minimum bid price rule the evening of April 16, 2020.
Despite the temporary regulatory relief provided by the suspension of the minimum bid price rule, the Company has decided to comply with Nasdaq’s delisting request as a result of several factors.
First, the only qualitative factor cited in the Nasdaq letter of non-compliance was the failure to satisfy the $1.00 minimum bid price. With the catastrophic impact of the coronavirus pandemic, the Company’s common stock share price has deteriorated significantly, to a point where it does not believe that the $1.00 compliance is possible through organic business activities prior to June 30, 2020.
Second, the Company has evaluated a number of possible corporate transactions with third parties that could possibly facilitate Nasdaq compliance. In every instance, the completion of such transactions would likely require a highly aggressive corporate restructuring, including a significant reverse split and the increase in authorized and outstanding shares above the current shareholder approved limits.
Lastly, none of the prospective merger candidates expressed an interest in retaining the existing assets of the Company in shareholder hands due to a desired reverse merger. The Company has evaluated the significant short term cash expenses required to complete such a speculative transaction, as well as the protracted regulatory approval process, coupled with the likely extreme dilution required to existing shareholder’s ownership and determined that the best path to preserve shareholder value is to accept the requested delisting request.
“The Company believes our current patent portfolio, expected future royalty income, and emerging commercial application for our patent portfolio should not be taken out of our shareholder’s hands in the immediate future through a possible reverse merger,” commented Scott Mahoney, CEO of Taronis. “We also wish to limit further dilution wherever possible, and all of the transactions we have evaluated would require a very sizable reverse split ratio that we believe would destroy much of our shareholder’s value.”
“We believe that once the short term disruptions to our business have passed, in the coming quarters, we will be able to resume our sterilization technology commercialization efforts. We also hope to eventually be able to regain momentum with hotels, restaurants, retirement homes, hospitals and other clients of Water Pilot.”
“In the short term, we will continue to evaluate a wide range of corporate initiatives to help unlock shareholder value on every front. These are extremely uncertain and unique times, and we are going to explore every avenue possible for our shareholders,” concluded Mr. Mahoney.
#49254
Re: Chicharros USA - bolsa internacional
Yo, desde mi humilde opinión de novato, te digo que para chicharros estoy probando IB en lugar de DeGiro. Por 3 razones principales:
1. Degiro no me permite poner dos órdenes para el mismo stock. Y para los chicharros a mí me parece fundamental, porque me gusta marcar un stoploss y un take profit.
2. Los datos van con 15 minutos de retraso en la mayoría de stocks de USA.
3. El margen de precio para el valor del stoploss/take profit es de un 20% (más o menos, creo recordar). Para unos puede ser suficiente y para otros no. A mí no me mola.
Y le veo más desventajas, pero con esas me vale para probar otro. Y ojo, que a lo mejor tienen solución en Degiro, pero he leído la ayuda y parece que no lo permiten por política.
1. Degiro no me permite poner dos órdenes para el mismo stock. Y para los chicharros a mí me parece fundamental, porque me gusta marcar un stoploss y un take profit.
2. Los datos van con 15 minutos de retraso en la mayoría de stocks de USA.
3. El margen de precio para el valor del stoploss/take profit es de un 20% (más o menos, creo recordar). Para unos puede ser suficiente y para otros no. A mí no me mola.
Y le veo más desventajas, pero con esas me vale para probar otro. Y ojo, que a lo mejor tienen solución en Degiro, pero he leído la ayuda y parece que no lo permiten por política.
#49255
Re: Chicharros USA - bolsa internacional
FET
Pillaros algunas acciones. Van a llevarla muy arriba. Ayer la empresa declaró dividendo y da opción de compra de acciones comunes a $2,64.
Dividendo: https://www.otcmarkets.com/filing/html?id=14110776&guid=NpJHUHCNU1EEj8h
#49256
Re: Chicharros USA - bolsa internacional
IMGN
Ya tenemos resultados financiero por debajo de expectativas...
Pero por otra parte,
Ya tenemos resultados financiero por debajo de expectativas...
Pero por otra parte,
- Present initial data from the FORWARD II platinum-agnostic doublet cohort evaluating mirvetuximab in combination with bevacizumab in an oral presentation at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting in May.
- Present pre-clinical data evaluating our next generation anti-folate receptor alpha (FRα) ADC, IMGN151, in ovarian cancer and other tumor types in a poster at the virtual American Association for Cancer Research (AACR) Annual Meeting in June.
Veremos si pesan más los malos resultados financieros o el efecto ASCO...
Yo me decanto por ASCO....
En breve, saldremos de dudas...
Un saludo
"“During the last quarter, we moved forward with our registration studies for mirvetuximab and advanced our portfolio of earlier-stage candidates, while adapting to meet the evolving challenges of the COVID-19 pandemic,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “Our lead program remains on track with the initiation of our pivotal SORAYA trial and patient enrollment in our confirmatory MIRASOL trial progressing as anticipated. In parallel, we continue to follow our FORWARD II combination cohorts and we are pleased to have initial data from our Avastin expansion cohort in platinum-agnostic ovarian cancer selected for a virtual oral presentation at ASCO in May. IND-enabling activities for IMGC936, our novel ADAM9-targeting ADC, continue on plan with an IND submission anticipated by the end of this quarter and we look forward to presenting pre-clinical data on IMGN151, our next generation anti-FRα ADC being investigated in tumors with a broad range of FRα expression, at the virtual AACR Annual Meeting in June.”
Enyedy added, “Having generated approximately $98M in net proceeds through a follow-on offering in January, we are in a strong financial position with our anticipated cash runway extended well into 2022. Drawing on the organizational resilience built over the last year, our team has risen to the challenge of COVID-19 to ensure that we can meet the needs of our patients around the globe. We have put in place business continuity plans to allow us to operate effectively in a virtual working environment, actively monitor our progress in our key studies, and rapidly adapt in response to new developments. Through these efforts, we seek to maintain the momentum we have generated in the business throughout 2020.”
"ImmunoGen had $247.3 million in cash and cash equivalents as of March 31, 2020, compared with $176.2 million as of December 31, 2019, and had $2.1 million of convertible debt outstanding in each period. Cash used in operations was $(28.3) million for the quarter ended March 31, 2020, compared with cash provided by operations of $10.2 million for the quarter ended March 31, 2019. The prior year period benefited from $65.2 million of net proceeds generated from the sale of the Company’s residual rights to Kadcyla® (ado-trastuzumab emtasine) royalties in January 2019. Net proceeds from the sale of equipment were $1.4 million for the first quarter of 2020 compared with capital expenditures of $(2.1) million for the first quarter of 2019. "
"ImmunoGen had $247.3 million in cash and cash equivalents as of March 31, 2020, compared with $176.2 million as of December 31, 2019, and had $2.1 million of convertible debt outstanding in each period. Cash used in operations was $(28.3) million for the quarter ended March 31, 2020, compared with cash provided by operations of $10.2 million for the quarter ended March 31, 2019. The prior year period benefited from $65.2 million of net proceeds generated from the sale of the Company’s residual rights to Kadcyla® (ado-trastuzumab emtasine) royalties in January 2019. Net proceeds from the sale of equipment were $1.4 million for the first quarter of 2020 compared with capital expenditures of $(2.1) million for the first quarter of 2019. "